Cambridge Healthtech Institute’s 3rd Annual
Overcoming Formulation Challenges for Biopharmaceutical Development:
Formulation and Process Optimization, Analytics, Device Integration and New Biologics
August 3-4, 2015
Part of CHI's 7th Annual The Bioprocessing Summit
August 3-7, 2015 | Westin Copley Place Hotel | Boston, Massachusetts
The popular third annual Overcoming Formulation Challenges for Biopharmaceutical Development conference will cover latest trends and challenges in biologic formulations development, process optimization, manufacturing, and device and packaging considerations for existing and emerging protein therapeutics. The conference will showcase case studies, especially unpublished and innovative work, on the use of the effective scale up strategies, excipient induced instability, process challenges, fill finish challenges, and predictive tool for rapid formulation and stability screening. We invite you to attend to learn from and network with the leading experts from around the world in the field of biologics formulation development.
Transformational Science: Moving From the Challenges of High Concentration mAbs to Meeting the Needs of Highly Potent Bispecifics
Sachin Dubey, Ph.D., Head of Formulation Development, Process Development, Glenmark Pharmaceuticals SA
Overcoming Formulation Challenges for Drug-Device Combination Products
Jamie Tsung, Ph.D., Principal Scientist, Momenta Pharmaceuticals, Inc.
Considerations and Approaches for Late Stage Formulation Development of Biologics
Hardeep Samra, Ph.D., Senior Scientist, Formulation Sciences, MedImmune, Inc.
Critical Considerations for Surfactant Stability in Biopharmaceutical Formulations
Sandeep Yadav, Ph.D., Scientist, Late Stage Pharmaceutical Development, Genentech, Inc.
Challenges in Co-Formulating Polysorbates and Preservatives in Multi-Use Biologics Formulations
Shuai Shi, Ph.D., Associate Principal Scientist, Sterile Product and Analytical Development, Merck
QbD in Late Stage Formulation Optimization - A Case Study
Mark Yang, Ph.D., Director, Fill Finish Development, Genzyme - a Sanofi Company
Mixing Monoclonal Antibody Formulations Using Bottom-Mounted Mixers – Impact of Mechanism and Design on Drug Product Quality
Yuh-Fun Maa, Ph.D., Principal Engineer, Pharmaceutical Processing and Technology Development, Genentech, Inc.
Stability Challenges for Protein Therapeutics: Anticipating Aggregation Phenomena at Early Development Stage
Joël Richard, Ph.D., Senior Vice President Peptides, Technical Operations, Ipsen
Strategy for Characterization and Control of Submicron and Subvisible Particles in Biologics
Nataliya Afonina, Ph.D., President and Principle Consultant, AN Biologics Consulting LLC
Addressing the Gaps in Particle Measurements for Biotherapeutic Solutions
Reema Raghavendra, M.S., MBA, Scientist II, Global Protein Sciences, AbbVie, Inc.
For more details on the conference, please contact:
For exhibit & sponsorship opportunities, please contact: